Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place this week ...

and anticoagulant Xarelto (rivaroxaban), and BMS' blood thinner Eliquis (apixaban) are among the 10 medicines elected for the first round of Medicare price reductions, which are due to come into ...

ICER isn't officially involved in the price negotiations introduced under the Inflation Reduction Act (IRA), but contributed a "special report" on Bristol Myers Squibb and Pfizer’s Eliquis ...

A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb's Eliquis (Apixaban)-USD 12 billion, among others ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Bristol Myers Squibb’s history is steeped in medical innovation, and its cardiovascular portfolio is no exception. The company’s legacy spans over 70 years of groundbreaking work, from pioneering ...

Medically reviewed by Femi Aremu, PharmD Borage is an herb from the Borago officinalis plant, which grows across the Middle ...